Trial Profile
Safety and efficacy of AGN 203818 in patients with painful diabetic peripheral neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2008
Price :
$35
*
At a glance
- Drugs Rezatomidine (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- 10 Dec 2007 Status changed from recruiting to completed.
- 24 Oct 2006 Status change
- 09 Oct 2006 New trial record.